Company Oramed Pharmaceuticals Inc. Deutsche Boerse AG
Equities
OJU1
US68403P2039
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.179 EUR | +0.09% | +7.60% | +4.21% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Solutions
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Israel
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -50.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13-04-13 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
Zach Herschfus
IRC | Investor Relations Contact | - | - |
Netanel Derovan
LAW | General Counsel | - | 22-01-08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
Arie Mayer
BRD | Director/Board Member | 67 | 19-12-04 |
Benjamin Shapiro
BRD | Director/Board Member | 40 | 23-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 40,519,160 | 35,939,036 ( 88.70 %) | 0 | 88.70 % |
Company contact information
Oramed Pharmaceuticals, Inc.
1185 Avenue of the Americas 3rd Floor
10036, New York
+844 967 2633
http://www.oramed.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ORMP Stock
- OJU1 Stock
- Company Oramed Pharmaceuticals Inc.